[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100283112":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":28,"centralContacts":33,"locations":42,"responsibleParty":65,"collaborators":68,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":75,"sex":81,"minAge":27,"maxAge":27,"enrollmentInfo":82,"targetDuration":27,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":27,"overallStatus":45,"whyStopped":27,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Hôpital Necker-Enfants Malades","OTHER",[8,13,17],{"label":9,"type":6,"description":10,"interventionNames":11},"Cystic fibrosis, treated","Cystic fibrosis patients treated either by Ivacaftor or by the association Ivacaftor-Lumacaftor",[12],"Procedure: Nasal swab; rectal biopsy.",{"label":14,"type":6,"description":15,"interventionNames":16},"Cystic fibrosis, non treated","Cystic fibrosis patients, non treated by a CFTR modulator",[12],{"label":18,"type":6,"description":19,"interventionNames":20},"Non-Cystic fibrosis","Patients in whom cystic fibrosis diagnosis has been suspected, but excluded by physiological and genetic investigations",[12],[22],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"PROCEDURE","Nasal swab; rectal biopsy.","Nasal epithelial cells will be obtained by nasal swabs from patients of the three arms; intestinal epithelial cells will be obtained, by rectal biopsy, only from patients treated by CFTR modulators.",[14,9,18],null,[29],{"name":30,"affiliation":31,"role":32},"Aleksander Edelman, phD","APHP","STUDY_DIRECTOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":27,"email":38},"Isabelle Sermet, MD, PhD","CONTACT","33 1 44 49 48 87","isabelle.sermet@aphp.fr",{"name":40,"role":36,"phone":27,"phoneExt":27,"email":41},"Jean-Louis Pérignon, MD, PhD","jean-louis.perignon@aphp.fr",[43],{"facility":44,"status":45,"city":46,"state":27,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Necker Hospital","RECRUITING","Paris","75014","France","FR",{"type":51,"coordinates":52},"Point",[53,54],2.3488,48.85341,{"lat":54,"lon":53},[57,61,63],{"name":58,"role":36,"phone":59,"phoneExt":27,"email":60},"SERMET Isabelle, Professor","01 44 49 48 87","isabelle.sermet@nck.aphp.fr",{"name":62,"role":36,"phone":59,"phoneExt":27,"email":60},"LE Bourgeois Muriel, MD",{"name":58,"role":64,"phone":27,"phoneExt":27,"email":27},"PRINCIPAL_INVESTIGATOR",{"type":64,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":27,"oldOrganization":27},"Isabelle Sermet-Gaudelus","Professor",[69,71],{"name":70,"class":6},"Association Mucoviscidose-ABCF2",{"name":72,"class":6},"Vaincre la Mucoviscidose","100283112","surrogate-markers-of-response-to-new-therapies-in-cystic-fibrosis-patients-100283112",false,"NCT02965326","Surrogate Markers of Response to New Therapies in Cystic Fibrosis Patients","Personalized Therapy of Cystic Fibrosis: Set-up of Response Markers","BIO-CFTR","Inclusion Criteria:\n\n* Cystic fibrosis patients treated by CFTR modulators (Ivacaftor or the association Ivacaftor-Lumacaftor)\n* Cystic fibrosis patients non treated by CFTR modulators\n* Patients in whom cystic fibrosis diagnosis has been suspected, but excluded by physiological and genetic investigations\n\nExclusion Criteria:\n\n* pregnant or lactating women\n* contraindication to nasal swab\n* contraindication to rectal biopsy","ALL",{"count":83,"type":84},75,"ESTIMATED","INTERVENTIONAL",[87],"NA","The purpose of this study is to determine which biological marker, or association of biological markers, best predict clinical response of cystic fibrosis patients to CFTR modulators.",[90],"Cystic Fibrosis","2024-03-08",{"date":93,"type":94},"2024-03-12","ACTUAL",{"date":96,"type":94},"2016-05",{"date":98,"type":84},"2026-10",{"name":5,"class":6},1]